The phase III clinical trial Keynote 048 sanctioned the introduction of this agent as first-line treatment for patients with (R/M) HNSCC with a PD-L1 combined positive score (CPS) ≥1 [7]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.